<DOC>
	<DOCNO>NCT01953601</DOCNO>
	<brief_summary>This study consist two part , Part I Part II . The purpose Part I study assess efficacy safety verubecestat ( MK-8931 ) compare placebo administer 104 week treatment amnestic mild cognitive impairment ( aMCI ) due Alzheimer 's Disease ( AD ) , also know prodromal AD . Participants randomize receive placebo , 12 mg 40 mg verubecestat , daily . The primary study hypothesis Part 1 least one verubecestat dose superior placebo respect change baseline Clinical Dementia Rating scale-Sum Boxes ( CDR-SB ) score 104 week . Participants complete Part I study may choose participate Part II , long term double-blind extension ass efficacy safety verubecestat administer additional 260 week . In Part II , participant receive either 12 mg 40 mg verubecestat , daily .</brief_summary>
	<brief_title>Efficacy Safety Trial Verubecestat ( MK-8931 ) Participants With Prodromal Alzheimer 's Disease ( MK-8931-019 )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>1 . Diagnosis prodromal AD , include follow : 1 . History subjective memory decline gradual onset slow progression least one year corroborate informant , 2 . Objective impairment episodic memory memory test perform Screening , 3 . Does meet criterion dementia , AND 4 . Positive Screening amyloid image PET scan use [ 18F ] flutametamol tracer positive Screening CSF tau : amyloidβ42 ( Aβ42 ) ratio 2 . Able read 6th grade level equivalent 3 . If participant receive acetylcholinesterase inhibitor memantine , dose must stable least three month Screening 4 . Must reliable competent trial partner/informant close relationship participant willing accompany participant require trial visit , monitor compliance administration trial medication 5 . Agree inform general practitioner participation study Inclusion Criteria Extension Period ( Part II ) : 1 . Tolerated study drug complete initial 104week period trial ( Part I ) 2 . Participant must reliable competent trial partner must close relationship subject 1 . History stroke 2 . Evidence clinically relevant neurological disorder disease study ( i.e. , prodromal AD ) 3 . History seizure epilepsy within last 5 year 4 . Evidence clinically relevant unstable psychiatric disorder , exclude major depression remission 5 . Participant imminent risk selfharm harm others 6 . History alcoholism drug dependency/abuse within last 5 year Screening 7 . Participant magnetic resonance imaging ( MRI ) scan obtain within 12 month Screening unwilling eligible undergo MRI scan Screening Visit . With Sponsor approval , head compute tomography ( CT ) scan may substitute MRI scan evaluate eligibility 8 . History hepatitis liver disease active within 6 month prior Screening 9 . Recent ongoing , uncontrolled , clinically significant medical condition within 3 month Screening 10 . History malignancy occur within 5 year Screening , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , localize prostate carcinoma 11 . Clinically significant vitamin B12 folate deficiency 6 month Screening 12 . Use investigational drug participation clinical trial within 30 day Screening 13 . History hypersensitivity reaction three drug 14 . Has human immunodeficiency virus ( HIV ) medical history 15 . Participant unwilling contraindication undergo PET scan include limited claustrophobia , excessive weight girth 16 . History current evidence long QT syndrome , correct QT ( QTc ) interval ≥470 millisecond ( male participant ) ≥480 millisecond ( female participant ) , torsades de point 17 . Close family member ( include trial partner , spouse child ) among personnel investigational sponsor staff directly involve trial Exclusion Criteria Extension Period ( Part II ) : 1 . Participant imminent risk selfharm harm others 2 . Has develop recent ongoing , uncontrolled , clinically significant medical psychiatric condition 3 . Results safety assessment ( e.g. , laboratory test ) perform participant end Part I clinically unacceptable Investigator 4 . Has develop form dementia AD</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>